Cross‐Interaction Chromatography‐Based QSAR Model for Early‐Stage Screening to Facilitate Enhanced Developability of Monoclonal Antibody Therapeutics-Reference-Cited by-同舟云学术

Cross‐Interaction Chromatography‐Based QSAR Model for Early‐Stage Screening to Facilitate Enhanced Developability of Monoclonal Antibody Therapeutics

Published:2019-04-17 Issue:8 Volume:14 Page:1800696
ISSN:1860-6768
Container-title:Biotechnology Journal
language:en
Short-container-title:Biotechnol. J.

Author:

Kizhedath Arathi¹,Karlberg Micael¹,Glassey Jarka¹^ORCID

Affiliation:

1. School of Engineering, Newcastle UniversityNewcastle upon Tyne NE17RU UK

Funder

H2020 Marie Sklodowska-Curie Actions

Publisher

Wiley

Subject

Molecular Medicine,Applied Microbiology and Biotechnology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/biot.201800696

Reference64 articles.

1. EvaluatePharma®. World Preview 2016 Outlook to 2022. EvaluatePharma http://info.evaluategroup.com/rs/607‐YGS‐364/images/wp16.pdf(accessed: January 16 2017) 2016.

2. EvaluatePharma®. World Preview 2017 Outlook to 2022 10th ed. 2017.

3. EvaluatePharma®. World Preview 2018 Outlook to 2024 10th ed. 2018.

4. Solubility Challenges in High Concentration Monoclonal Antibody Formulations: Relationship with Amino Acid Sequence and Intermolecular Interactions

5. Use of In Vitro Assays to Assess Immunogenicity Risk of Antibody-Based Biotherapeutics

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Current state of implementation of in silico tools in the biopharmaceutical industry—Proceedings of the 5th modeling workshop;Biotechnology and Bioengineering;2024-06-10

2. Non-specificity as the sticky problem in therapeutic antibody development;Nature Reviews Chemistry;2022-11-14

3. A multiscale modeling method for therapeutic antibodies in ion exchange chromatography;Biotechnology and Bioengineering;2022-10-24

4. A Descriptor Set for Quantitative Structure‐property Relationship Prediction in Biologics;Molecular Informatics;2022-03-29

5. Model-Based Risk Assessment of mAb Developability;Optimization of Pharmaceutical Processes;2022